In Vivo Efficacy of a Broad-Spectrum Antiviral Combination Against Yellow Fever in a Hamster Model.

Abbie E Weight, Hunter Stanger, Robert J Geraghty, Laurent F Bonnac, Justin G Julander

Abstract read

In one paragraph

Article in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abbie E WeightInstitute for Antiviral Research, Utah State University, Logan, UT 84322, USA.ORCID 0000-0001-8720-1304

Hunter StangerInstitute for Antiviral Research, Utah State University, Logan, UT 84322, USA.

Robert J GeraghtyCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-0560-6509

Laurent F BonnacCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-4970-8822

Justin G JulanderInstitute for Antiviral Research, Utah State University, Logan, UT 84322, USA.

Funding

Task B6: In Vitro Assessment for Antimicrobial Activity Against Respiratory Viruses, Including SARS-CoV-275N93019D00021 · NIAID · UTAH STATE UNIVERSITY · PI JULANDER, JUSTIN · 2019 to 2025

$7.3M

NIAID/NIH contract HHSN272201700041I, Task Orders A51 and A91.NIAID NIH HHS 75N93019D00021NIAID NIH HHS HHSN272201700041I

6 · The paper itself

Abstract

Yellow fever virus (YFV) recurrently causes severe outbreaks in tropical regions of South America and Africa and an average of 30 to 40 thousand deaths worldwide each year. An effective vaccine is available but the coverage of the population in countries at risk is not optimal. No antivirals are currently approved for YFV treatment. Herein, we describe the evaluation of 6-MMPr, a

Indexed as

AmidesAntiviral AgentsPyrazinesYellow FeverYellow fever virusAnimalsCricetinaeDisease Models, AnimalDrug Therapy, CombinationMesocricetusTreatment OutcomeVirus ReplicationAmidesAntiviral AgentsfavipiravirPyrazinesanimal modelbroad-spectrumdrug combinationfavipiravirflavivirusespandemic preparednessyellow fever

Identifiers

PMID41011825

DOI10.3390/pathogens14090925

PMCPMC12472584

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.